Hikma's Generic Fludrocortisone Acetate Receives Approval in the U.S.
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application (ANDA) for Fludrocortisone Acetate Tablets USP, 0.1 mg.
In October last year The Competition and Markets Authority (CMA) provisionally found that three drug firms - Aspen, Amilco and Tiofarma - signed an illegal agreement that resulted in significant price hikes for an essential medicine.
The CMA has announced Tiofarma admits taking part in an anti-competitive agreement with Amilco and Aspen which resulted in huge price increase in fludrocortisone acetate tablets.
The Competition and Markets Authority (CMA) said the settlement follows an investigation into collusion between Aspen and rival firms to keep competitors to its Fludrocortisone 0.1 mg tablets off the market.